Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF OCU410ST-MODIFIER GENE THERAPY-FOR STARGARDT DISEASE”
The Stargardt global market size is forecasting explosive growth with expected market size to reach $1.4b by 2023.
“Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).”-Coherent market insights
$ocgn Pipeline is full of big hitters. pic.twitter.com/DkCNJajHjI
— TheUrbanFarmer (@NattaCop) November 10, 2023
“Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates”
https://www.biorxiv.org/content/10.1101/2023.11.06.565765v1
OCGN
Shankar Musunuri was “Global Operations Team Leader for one of the most successful launches in vaccine history, Prevnar 13®.”
https://entrepreneurship.duke.edu/profile/shankar-musunuri-mba-06/
OCGN
Here comes the RS! Lmao, pos ceo an company. This scammer did the same thing to his previous company, look it up.he is a thief folks imo, stay away from a scam
AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies
“Christopher J. Layton owns shares in Ocugene, a gene therapy company. Jason C. Steel has been a consultant for Ocugene and owns intellectual property in breast cancer gene therapy.”
https://link.springer.com/article/10.1007/s40259-023-00629-y
OCGN 8k for 180 day extension
https://www.sec.gov/ix?doc=/Archives/edgar/data/1372299/000162828023036087/ocgn-20231102.htm
Thu, 2nd Nov 2023 “Nasdaq Determines Ocugen, Inc. Eligible for an Additional 180-Day Period, or Until April 29, 2024, to Regain Compliance with the Minimum Bid Price Requirement”
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/event/1860803306?utm_source=braze&utm_medium=email&utm_campaign=Critical+Updates&utm_content=Email
Thanks, urban!
Don't know about ocgn’s Operation Next Gen product, how it will perform or why we were chosen to be a part of Next Gen? Below are some important facts and links.
Phase 3 safety study for our ChAd vector vaccine via Nasal delivery:
https://www.nature.com/articles/s41541-023-00717-8
Phase 3 trial for our Inhalation delivery device:
https://www.prnewswire.com/news-releases/convidecia-phase-iii-results-published-in-the-lancet-301450673.html
Phase1 efficacy results using both our ChAd vector vaccine and our inhalation delivery device.
Quote- "so efficient at targeting the lungs and upper airways that it can achieve maximum protection with a small fraction of the dose of current vaccines - possibly as little as 1 per cent - meaning a single batch of vaccine could go 100 times farther, the researchers say.”
https://brighterworld.mcmaster.ca/articles/researchers-confirm-newly-developed-inhaled-vaccine-delivers-broad-protection-against-sars-cov-2-variants-of-concern/
Haha. Quite the choice for a username. Welcome to ihub, fellow long.
OCGN
Connie Collingsworth, a co-founder of the Bill and Melinda Gates Foundation, has become a valuable addition to Ocgn’s Business Advisory Board (BAB).
Ocgn is actively gearing up for the global commercialization of their next-generation vaccines and has strategically enlisted the most renowned experts to help support their efforts.
https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-connie-collingsworth-joins-business
Proud to be apart of this company and excited to see them succeed in bringing their pipeline to market, thanks for all the excellent DD!
$OCGN
“Clinical trials are scheduled to start in early 2024, led by NIAID with funding from Project NextGen. After completing the trial, NIAID and Ocugen (OCGN) will assess the data to determine the next steps for the program.“
https://seekingalpha.com/news/4019331-ocugen-mucosal-vaccine-picked-us-covid-initiative
If you are curious about our next gen platform, watch this video showcasing it in action. Our partner Cansino(company who developed Aerogen solo delivery system) has already proven its superiority with their successful launch of Convidecia Air in China.
$ocgn take a moment and learn about what’s to come.#LetsDoThis 🚀 pic.twitter.com/bWyDNdP0Ay
— TheUrbanFarmer (@NattaCop) June 12, 2023
We truly possess the best of both worlds. Own the only two approved delivery systems currently being used today while owning the most cost effective and safe next gen vaccine platform.
Our viral vector platform can carry/deliver a very wide range of messages, from vaccines to gene therapies our vectors can carry the message and deliver it safely. Our platform doesn’t require unstable messaging like Mrna and doesn’t need any toxic adjuvants to trigger an immune response. Our vectors trigger a immune response the same way nature intended.
Introduce a message to a vector, place it in a chamber, and that vector will naturally multiply and each new vector will carry the same message that it multiplied from. Utilizing nature as our own manufacturing system is as logical as it is cost effective.
In essence, our vaccine platform is versatile and can deliver a wide range of messages naturally. It offers us a cost-effective, genuinely safe vaccine option with production that can be 100% made in America.
Moreover, this vector infrastructure will be utilized for Ocugen’s other treatments, including their cure for blindness and more. It’s a complete game-changer for the market in general and makes for a truly next-gen platform.
Americans will finally get a bang out of our hard earned bucks. Soon people won’t need to inject an unstable product with potentially harmful ingredients to gain the immunity they need. I can’t be alone when I say I’d rather inhale some air from a cup or take some drops in the nose to gain long lasting protection.
Ocugen’s platform may sound like a no 🧠’er and that’s because it is in every single way. 🍻
Thank you for your fine work Sgunderbarth! Soon we will got rewarded by bouncing back in the Dollarland!
OCGN Q3 conference call Nov 9. https://ir.ocugen.com/news-releases/news-release-details/ocugen-host-conference-call-thursday-november-9-830-am-et
8k 180 day extension. https://www.sec.gov/Archives/edgar/data/1372299/000162828023036087/ocgn-20231102.htm
OCGN
I've bought today at .357 just for the love of risk! I believe that something good can still happen!
It’s evident that the viral vector platform stands out as the superior Next Gen solution. But what makes Ocugen truly remarkable is how it enhances this platform. Ocugen’s ChAd Vectors tackle the platform’s concerns effectively.
Utilizing ChAd(a virus unique to monkeys) Vectors eliminates the risk of host infection. Our ChAd vectors simplify viral vector production, ensuring cost-effective manufacturing. They also avoid reduced immune response due to pre-existing immunity. Moreover, our ChAd Vectors expedite development, reducing the timeline to just 10-12 weeks.
Ocugen has taken an already superior platform and successfully overcome its limitations, offering a solution without drawbacks. The NIH has chosen Ocugen’s platform and delivery devices because the science is crystal clear. Ocugen owns the Next Gen platform that’s poised to revolutionize the industry—a stable, safe, naturally manufactured vaccine platform with a delivery system that mimics nature’s intent.
Soon, we won’t need to inject potentially toxic ingredients to combat respiratory illnesses. 🍻
$ocgn It’s evident that the viral vector platform stands out as the superior Next Gen solution. But what makes Ocugen truly remarkable is how it enhances this platform. Ocugen’s ChAd Vectors tackle the platform’s concerns effectively.
— TheUrbanFarmer (@NattaCop) October 14, 2023
Utilizing ChAd(a virus unique to monkeys)… pic.twitter.com/YhN06OnEIt
This comparison test should be a big tell for everyone. Wonder why they are not making us do phase 2 trials like they are with the others?
If you look at the next gen BARDA slides you would see our vaccine and platform(Bharat/Cansino) is passed the phase 3 section and on the already approved section.
Why would one do a head to head comparison study? They are done when there's multiple treatment options available to patients on the market, a head-to-head study establishes how well these treatments compare to each other.
These studies are mostly done by the Industry and it's because they want to compare their product against the competitions. Lucky for us we're our own competition.
They want to bring a next gen product to market to combat the next waves to come. Ask yourself, who tf else would be able to do that besides us?
Profit off the clueless, the facts are not incredibly obvious, one must take time to learn them and this creates once in a lifetime discounts. 🍻
$ocgn This comparison test should be a big tell for everyone. Wonder why they are not making us do phase 2 trials like they are with the others?
— TheUrbanFarmer (@NattaCop) October 17, 2023
If you look at the next gen BARDA slides you would see our vaccine and platform(Bharat/Cansino) is passed the phase 3 section and on… pic.twitter.com/3WlFUyen1n
Same bears who were saying “it's to bad Ocugen owns Covaxin and not BB's nasal vaccine because that's the future of vaccines”. Now act like Ocu500 is not even developed after Ocugen gained exclusive rights.
"The study involving Ocugen's vaccine will be administered via both intranasal and inhaled routes and is designed to help answer an important question - does an inhaled COVID-19 vaccine provide greater immune response than the same vaccine administered through a nasal spray."
They want you to believe Ocu500 is not even phase 1 ready. They want you to believe that the NIH is administering a phase 0 drug to people without knowing the safety profile, the side effects or if it will even work.
They want you to only see the broad description of NIH's role in Next Gen instead of the actual Pr. They think by saying "it's not a head to head study, it's a head to head comparison of delivery systems", will convince you that our platform is pre clinical. They think that you're stupid. 🤣
BARDA requested recommendations from the National Biodefense Science Board on priority product attributes(A Key goal of #ProjectNextGen is to invest in favorable attributes).
Ty Dr. Fernandes, Ocugen’s lead Director/Chairperson of the National Biodefense Science Board.👏🍻
$ocgn BARDA requested recommendations from the National Biodefense Science Board on priority product attributes(A Key goal of #ProjectNextGen is to invest in favorable attributes).
— TheUrbanFarmer (@NattaCop) November 1, 2023
Ty Dr. Fernandes, Ocugen’s lead Director/Chairperson of the National Biodefense Science Board.👏🍻 pic.twitter.com/dBFQpzxSq9
A key goal of #ProjectNextGen is to invest in #COVID19 vaccine and therapeutic candidates that have favorable attributes that potentially increase access to prevention and treatment by better meeting the needs of America’s diverse population. pic.twitter.com/eJUErKkq5J
— BARDA (@BARDA) October 31, 2023
Never happen pal! Bank on that $$$$$
Short is the only way
Its going to .10!! Junk
180 day extension due soon. Holding. OCGN
Wont move anywhere,shorts are shorting the F*** out of it just like every other stock
Look at what he did to Nuron Biotech. Yes, raising money to pay themselves. Great use of investor financing, if you believe this is a rockstar team that is going to make it all happen.
$0.40 is not a floor .. we can break through that. Come on team, let's go for $0.30 next week. They are years and years away from commercialization of anything, and diverted all their funds from what might have been better opportunities to chase covid19 vaccines. Still are.
They need to be bought. Just not cheap enough yet.
40 cents! Free fall! Any one for $0.30? They have stopped their inhalation covid vaccine unless they get government approval. They got nothing.
😂 you are funny ..... $1 soon. What, the whole enterprise value?
Followers
|
226
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5670
|
Created
|
11/13/15
|
Type
|
Free
|
Moderators sgunderbarth |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |